ArticleMetabolic syndrome and related disorders2009
Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma.
Article in Metabolic syndrome and related disorders, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04298684 (Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes), which is not on this map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Pooled it
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
- Obesity and thyroid cancer: mechanisms and clinical implications.Frontiers in nutrition · 2026Review
- Papillary thyroid carcinoma and primary aldosteronism: A new syndrome or a mere association?World journal of clinical cases · 2025Article
- Article
- Global trend and disparity in the burden of thyroid cancer attributable to high body-mass index from 1990 to 2021 and projection to 2049: a systematic analysis based on the Global Burden of Disease Study 2021.BMC public health · 2025Article
- Epidemiological study of thyroid cancer at global, regional, and national levels from 1990 to 2021: an analysis derived from the Global Burden of Disease Study 2021.Frontiers in endocrinology · 2025Article
- Type 2 Diabetes, Obesity and Their Relation to the Risks of Thyroid Cancer.Physiological research · 2024Article
- Article
- Metabolic obesity phenotypes and thyroid cancer risk: A systematic exploration of the evidence.Obesity science & practice · 2024Review
- The Role of Body Mass Index (BMI) in Differentiated Thyroid Cancer: A Potential Prognostic Factor?Biomedicines · 2024Article
- The Role of Inositols in Endocrine and Neuroendocrine Tumors.Biomolecules · 2024Review
- Surgical management of the diabetic foot: The current evidence.World journal of orthopedics · 2024Review
- Thyroid cancer and insulin resistance.Reviews in endocrine & metabolic disorders · 2024Review
- Impact of Bariatric Surgery on Thyroid Morphology and Thyroid Function.Obesity surgery · 2023Article
- Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.Discover oncology · 2023Review
- Prevalence of Thyroid Nodules and Associated Clinical Characteristics: Findings from a Large Sample of People Undergoing Health Checkups at a University Hospital in Vietnam.Risk management and healthcare policy · 2023Article
- Metformin Decreases Serum Thyroglobulin Concentration in Nonmedullary Thyroid Carcinoma.Journal of the Endocrine Society · 2022Article
- Review
- Obesity and Thyroid Cancer Risk: An Update.International journal of environmental research and public health · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with insulin resistance (IR) have a higher prevalence of thyroid nodules. In the present study, we present original data showing that patients with differentiated thyroid carcinoma (DTC) also have a higher frequency of IR.
methodsTwenty women with DTC (group 1, G1) and 20 euthyroid individuals (control group, CG) were investigated for IR. G1 and CG subjects were matched in pairs by age, gender, and body mass index (BMI). The diagnosis of IR was made when the homeostasis model assesment of insulin resistance (HOMA-IR) index was higher than 2.5. According to the BMI, 20 women (10 with DTC and 10 of the CG) had a BMI < 25, whereas the other 20 had higher BMI values (overweight and obese patients).
resultsIR was present in the 50% of G1, but only in the 10% of the CG (P < 0.001). In the groups with lower BMI (<25), we found IR in 30% of G1 and no cases in the CG, whereas in those with BMI > 25 the IR was present in 70% of G1 and 20% of CG. There were no differences between the two subgroups regarding the time in which the IR tests were performed. IR was present in 56.3% of patient with papillary anol 25% of follicular thyroid carcinomas, respectively.
conclusionsWe conclude that such a high prevalence of IR would be an important risk factor for developing DTC, as it is well known with some other nonthyroid carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.